India’s first phase-three trial for an indigenous tetravalent dengue vaccine, DengiALL, was initiated by Panacea Biotec. Conducted across 19 sites, the trial involves over 10,335 healthy adults. The vaccine aims to address all four dengue serotypes. The Union Health Minister J P Nadda highlighted its significance in combating dengue and enhancing India’s vaccine development capabilities.3rd phase clinical trial of India’s dengue vaccine initiated
India’s first phase-three trial for an indigenous tetravalent dengue vaccine, DengiALL, was initiated by Panacea Biotec. Conducted across 19 sites, the trial involves over 10,335 healthy adults. The vaccine aims to address all four dengue serotypes. The Union Health Minister J P Nadda highlighted its significance in combating dengue and enhancing India’s vaccine development capabilities.
